8 tracked 13F filers disclose a position in AZTR as of the latest SEC 13F filings, a combined $1.3M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Stonepine Capital Management, LLC | $887K | 5.3M | ▲New +5.3M sh | Q2 2026 | |
| 2 | Nantahala Capital Management, LLC | $371K | 2.2M | ▲New +2.2M sh | Q2 2026 | |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | $16K | 95K | ▼−80% Reduced · −374K sh | Q2 2026 | |
| 4 | UBS Group AG | $7K | 30K | ▲30× Added · +29K sh | Q1 2026 | |
| 5 | StoneX Group Inc. | $5K | 29K | ▲+28% Added · +6K sh | Q2 2026 | |
| 6 | Tower Research Capital LLC (TRC) | $4K | 15K | ▲152× Added · +15K sh | Q1 2026 | |
| 7 | CITIGROUP INC | $399 | 2K | ▲New +2K sh | Q1 2026 | |
| 8 | FMR LLC | $35 | 150 | ▲New +150 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 2 funds opened a new position in AZTR and 2 added to an existing one, while 0 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| ABEONA THERAPEUTICS INCABEO | 4 funds | $35.3M |
| EVOLUS INCEOLS | 3 funds | $50.0M |
| ZEVRA THERAPEUTICS INCZVRA | 3 funds | $29.5M |
| GOGO INCGOGO | 3 funds | $27.0M |
| VERASTEM INCVSTM | 3 funds | $26.5M |
| ADMA BIOLOGICS INCADMA | 3 funds | $26.1M |
| OPUS GENETICS INCIRD | 3 funds | $13.1M |
| X4 PHARMACEUTICALS INCXFOR | 3 funds | $12.5M |
| SERVICE PROPERTIES TRUSTSVC | 3 funds | $9.1M |
| CODEXIS INCCDXS | 3 funds | $8.5M |
| TELA BIO INCTELA | 3 funds | $6.4M |
| INHIBIKASE THERAPEUTICS INCIKT | 3 funds | $6.3M |
Ranked by how many of AZTR's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Mar 29, 2024 | Staskey Norm | Chief Financial Officer | Buy (P) | 48K | $10K |
| Feb 13, 2024 | Salva Francisco D. | President and CEO, Director | Buy (P) | 333K | $100K |
| Feb 13, 2024 | Staskey Norm | Chief Financial Officer | Buy (P) | 3K | $990 |
| Feb 13, 2024 | Whitfill Travis | Chief Operating Officer, Director | Buy (P) | 15K | $5K |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Sell (S) | 78K | — |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Buy (P) | 198K | — |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Buy (P) | 70K | $349K |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Sell (S) | 509K | — |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Buy (P) | 1.3M | — |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Buy (P) | 456K | $2.3M |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Sell (S) | 82K | — |
| Jun 21, 2023 | BIOS Fund III NT, LP | 10% Owner | Buy (P) | 209K | — |
Connected entities for AZTR
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/AZTR/capital-change-brief"
Use Arkolith's capital_change_brief for AZTR. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for AZTR. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.